Health Care Sector Update for 12/04/2018: NVLN, RVNC, ARDS



Shutterstock photo

Top Health Care Stocks

JNJ, +0.4%

PFE, -1.5%

MRK, -0.9%

ABT, -3.1%

AMGN, -1.9%

Health care stocks extended their declines through Tuesday trading, with the NYSE Health Care Index dropping to more than 1% this afternoon while shares of health care companies in the S&P 500 were down nearly 2% as a group.

In company news, Novelion Therapeutics ( NVLN ) shares gained nearly 32% after one of the company’s largest shareholders urged the its board to consider all strategic options and “not simply choose the most expedient solution for debt-holders at the expense of the equity holders.” Healthcare Value Capital, which owns 1.8 million shares, or 9.52% of the outstanding shares, believes that what it calls chronic mismanagement and poor oversight by the board have caused “severe financial distress,” and that the intrinsic value of Novelion as a stand-alone entity far exceeds the $600 million under distressed conditions.

In other sector news,

(+) Revance Therapeutics ( RVNC ) Enters into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. for the exclusive rights to develop and commercialize the company’s DaxibotulinumtoxinA for injection (RT002) in mainland China, Hong Kong and Macau

(-) Aridis Pharmaceuticals, Inc. ( ARDS ) Says Cystic Fibrosis Foundation has more than doubled its research agreement for the clinical development of AR-501


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.









Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

Wealth Empire Newsletter
Register now for free updates and alerts

Subscribe By

Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.